List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5326883/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation. Leukemia, 2022, 36, 267-270.	7.2	14
2	Donor activating killer cell immunoglobulinâ€ŀike receptors genes correlated with Epstein–Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology, 2022, 196, 1007-1017.	2.5	4
3	Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies. Frontiers in Immunology, 2022, 13, 757002.	4.8	13
4	Treatment outcome and efficacy of therapeutic plasma exchange for transplant-associated thrombotic microangiopathy in a large real-world cohort study. Bone Marrow Transplantation, 2022,	2.4	5
5	Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome. BMC Cancer, 2022, 22, 11.	2.6	2
6	Donor NKG2C homozygosity contributes to CMV clearance after haploidentical transplantation. JCI Insight, 2022, 7, .	5.0	8
7	Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cellular and Molecular Immunology, 2022, 19, 482-491.	10.5	15
8	Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions. Oncology and Therapy, 2022, , 1.	2.6	0
9	Adoptive therapy with <scp>cytomegalovirus</scp> â€specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy. American Journal of Hematology, 2022, 97, 762-769.	4.1	14
10	Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression. Journal of Immunology, 2022, 208, 492-500.	0.8	5
11	Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study. Therapeutic Advances in Hematology, 2022, 13, 204062072210952.	2.5	5
12	The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 814334.	4.8	3
13	CMV infection combined with acute GVHD associated with poor CD8+ T-cell immune reconstitution and poor prognosis post-HLA-matched allo-HSCT. Clinical and Experimental Immunology, 2022, 208, 332-339.	2.6	6
14	PRDM1 Drives Human Primary T Cell Hyporesponsiveness by Altering the T Cell Transcriptome and Epigenome. Frontiers in Immunology, 2022, 13, 879501.	4.8	4
15	Multiomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graftâ€Versusâ€Host Disease. Advanced Science, 2022, 9, e2200978.	11.2	7
16	An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood, 2022, 140, 516-520.	1.4	18
17	Decoding lymphomyeloid divergence and immune hyporesponsiveness in G-CSF-primed human bone marrow by single-cell RNA-seq. Cell Discovery, 2022, 8, .	6.7	5
18	Anti–PD-1 antibody (sintilimab) plus decitabine as first-line treatment for patients with higher-risk myelodysplastic syndrome (MDS): Preliminary results from a single-arm, open-label, phase II study Journal of Clinical Oncology, 2022, 40, 7052-7052.	1.6	0

#	Article	IF	CITATIONS
19	Prognostic value of postâ€transplantation Wilms' tumor gene 1 expression in acute myeloid leukaemia subgroup according to different preâ€transplant disease status. International Journal of Laboratory Hematology, 2022, 44, .	1.3	0
20	The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in <i>CBFB–MYH11</i> â€positive acute myeloid leukaemia indicates poor prognosis. British Journal of Haematology, 2021, 192, 265-271.	2.5	13
21	Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Annals of Hematology, 2021, 100, 505-516.	1.8	4
22	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center. Annals of Hematology, 2021, 100, 1203-1212.	1.8	10
23	HCMV modulates câ€Mpl/IEXâ€1 pathwayâ€mediated megakaryo/thrombopoiesis via PDGFRα and αvβ3 recepto after alloâ€HSCT. Journal of Cellular Physiology, 2021, 236, 6726-6741.	ors 4.1	1
24	A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation. Chinese Medical Journal, 2021, 134, 1199-1208.	2.3	3
25	Acute Cholecystitis Following Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Features, Outcomes, Risk Factors, and Prediction Model. Transplantation and Cellular Therapy, 2021, 27, 253.e1-253.e9.	1.2	1
26	Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the MONITOR model in a nationwide multicenter study. American Journal of Hematology, 2021, 96, 561-570.	4.1	5
27	Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2097-2107.	2.4	9
28	Unmanipulated haploidentical hematopoietic stem cell transplantation is an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy. Leukemia, 2021, 35, 3092-3100.	7.2	22
29	Predictive Value of Dynamic Peri-Transplantation MRD Assessed By MFC Either Alone or in Combination with Other Variables for Outcomes of Patients with T-Cell Acute Lymphoblastic Leukemia. Current Medical Science, 2021, 41, 443-453.	1.8	3
30	Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies. Bone Marrow Transplantation, 2021, 56, 2723-2731.	2.4	4
31	Interferon-Î \pm as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 2949-2956.	1.3	14
32	Risk Stratification of Cytogenetically Normal Acute Myeloid Leukemia With Biallelic CEBPA Mutations Based on a Multi-Gene Panel and Nomogram Model. Frontiers in Oncology, 2021, 11, 706935.	2.8	3
33	Editorial: Recent Developments in Haploidentical Hematopoietic Cell Transplantation: Therapy and Complications. Frontiers in Immunology, 2021, 12, 746221.	4.8	2
34	PMLâ€RARA transcript levels at the end of induction therapy are associated with prognosis in nonâ€highâ€risk acute promyelocytic leukaemia with all†trans retinoic acid plus arsenic in frontâ€line therapy: longâ€term followâ€up of a singleâ€centre cohort study. British Journal of Haematology, 2021, 195, 722-730	2.5	3
35	Predicting mortality from intracranial hemorrhage in patients who undergo allogeneic hematopoietic stem cell transplantation. Blood Advances, 2021, 5, 4910-4921.	5.2	4
36	A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy. Blood Advances, 2021, 5, 5479-5489.	5.2	6

#	Article	IF	CITATIONS
37	A Scoring System for Predicting the Prognosis of Late-Onset Severe Pneumonia after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 870.e1-870.e7.	1.2	2
38	Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings. Annals of Hematology, 2021, 100, 555-562.	1.8	5
39	Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cellular and Molecular Immunology, 2021, 18, 1172-1185.	10.5	55
40	Haploidentical Stem Cell Transplantation for Acute Myeloid Leukemia: Current Therapies, Challenges and Future Prospective. Frontiers in Oncology, 2021, 11, 758512.	2.8	11
41	Prognostic value of RASD1 transcript levels in adult Philadelphia-negative B-cell acute lymphoblastic leukemia. Hematology, 2021, 26, 9-15.	1.5	0
42	All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood, 2021, , .	1.4	10
43	PRDM1 Is Sufficient for Inducing Human Primary T Cell Hyporesponsiveness and Implicates Low Gvhd Occurrence after Allo-HSCT. Blood, 2021, 138, 197-197.	1.4	1
44	Treatment Outcome and Efficacy of Therapeutic Plasma Exchange for Transplant-Associated Thrombotic Microangiopathy in a Real-World Large Cohort Study. Blood, 2021, 138, 1013-1013.	1.4	0
45	A Clinical Study of 15 Acute Leukemia Patients with Plasmacytoid Dendritic Cells Expansion. Blood, 2021, 138, 4468-4468.	1.4	0
46	Prevalence and Risk Factors of Antibodies to Class I and II Human Leukocyte Antigens in Haploidentical Allograft Candidates: A Prospective Study on 3805 Subjects. Blood, 2021, 138, 2880-2880.	1.4	0
47	All-Trans Retinoic Acid Plus Low-Dose Rituximab Vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP. Blood, 2021, 138, 15-15.	1.4	0
48	Machine-Learning Based Early Warning System for Prediction for Disseminated Intravascular Coagulation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Multicenter Study. Blood, 2021, 138, 2113-2113.	1.4	1
49	The Application of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in AML-MRC: A Single Center Case Control Study. Blood, 2021, 138, 2320-2320.	1.4	0
50	Comparison of Transplant Donor and Third-Party Donor Derived CMV-Specific T Cells for CMV Infection after Allogenic Stem Cell Transplantation. Blood, 2021, 138, 1701-1701.	1.4	0
51	Tacrolimus Plus High-Dose Dexamethasone Versus High-Dose Dexamethasone Alone As First-Line Treatment for Adult Immune Thrombocytopenia: The Phase 2, Open Label, Randomized Trial (TARGET) Tj ETQq	110 .7 8431	l4 æBT /Over
52	Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. Frontiers in Immunology, 2021, 12, 731435.	4.8	4
53	Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Oncology, 2021, 11, 773394.	2.8	8
54	First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)–specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clinical Infectious Diseases, 2020, 70, 1429-1437.	5.8	30

#	Article	IF	CITATIONS
55	NK cell reconstitution following unmanipulated HLA-mismatched/haploidentical transplantation compared with matched sibling transplantation. Science China Life Sciences, 2020, 63, 781-784.	4.9	5
56	A wave of Foxp3+ regulatory T cell accumulation in the neonatal liver plays unique roles in maintaining self-tolerance. Cellular and Molecular Immunology, 2020, 17, 507-518.	10.5	21
57	The Quantification of Minimal Residual Disease Pre―and Postâ€Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2020, 98, 75-87.	1.5	18
58	Effects of Granulocyte Colony-Stimulating Factor on Proliferation and Apoptosis of B Cells in Bone Marrow of Healthy Donors. Transplantation Proceedings, 2020, 52, 345-352.	0.6	2
59	Incidence, Risk Factors, Outcomes, and Risk Score Model of Acute Pancreatitis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1171-1178.	2.0	8
60	The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia. Annals of Hematology, 2020, 99, 73-82.	1.8	15
61	Reply to M. Shibusawa et al. Journal of Clinical Oncology, 2020, 38, 4224-4225.	1.6	0
62	Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2659-2670.	1.8	13
63	Th2 polarization in target organs is involved in the alleviation of pathological damage mediated by transplanting granulocyte colony-stimulating factor-primed donor T cells. Science China Life Sciences, 2020, 64, 1087-1096.	4.9	4
64	A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Advances, 2020, 4, 5846-5857.	5.2	5
65	Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1. Journal of Hematology and Oncology, 2020, 13, 52.	17.0	13
66	Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody. Bone Marrow Transplantation, 2020, 55, 1326-1336.	2.4	31
67	Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 2087-2097.	2.4	8
68	Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplantation, 2020, 55, 2035-2042.	2.4	11
69	Aging-induced IL27Ra signaling impairs hematopoietic stem cells. Blood, 2020, 136, 183-198.	1.4	53
70	miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. Molecular Therapy - Nucleic Acids, 2020, 20, 764-776.	5.1	28
71	Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene. Expert Review of Anticancer Therapy, 2020, 20, 453-464.	2.4	7
72	Correlation of CD19+CD24hiCD38hi B cells in coronary artery disease with severity of atherosclerosis. Chinese Medical Journal, 2020, 133, 1257-1258.	2.3	5

#	Article	IF	CITATIONS
73	CD8+CD161hi T cells are associated with acute graft-versus-host disease after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 1652-1654.	2.4	3
74	Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. Journal of Clinical Oncology, 2020, 38, 3367-3376.	1.6	69
75	Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates. Scientific Reports, 2020, 10, 2367.	3.3	3
76	Mutation topography and risk stratification for <i>de novo</i> acute myeloid leukaemia with normal cytogenetics and no nucleophosmin 1 (<i>NPM1</i>) mutation or Fmsâ€like tyrosine kinase 3 internal tandem duplication (<i>FLT3â€</i> ITD). British Journal of Haematology, 2020, 190, 274-283.	2.5	18
77	Frequency, Risk Factors, and Outcome of Active Tuberculosis following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1203-1209.	2.0	9
78	Autophagy in endothelial cells regulates their haematopoiesis-supporting ability. EBioMedicine, 2020, 53, 102677.	6.1	13
79	A retrospective analysis on anti-CD20 antibody–treated Epstein–Barr virus–related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 2649-2657.	1.8	2
80	Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting VÎ 2+T cells activities after hematopoietic transplantation for blood malignancies. , 2020, 8, e000208.		18
81	Osteoclast stimulatory transmembrane protein (OC‧TAMP) is a promising molecular prognostic indicator for multiple myeloma. European Journal of Haematology, 2020, 105, 185-195.	2.2	2
82	Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. Journal of Hematology and Oncology, 2020, 13, 27.	17.0	48
83	Different Effects of Pre-transplantation Measurable Residual Disease on Outcomes According to Transplant Modality in Patients With Philadelphia Chromosome Positive ALL. Frontiers in Oncology, 2020, 10, 320.	2.8	17
84	Comparison of central nervous system relapse outcomes following haploidentical vs identical-sibling transplant for acute lymphoblastic leukemia. Annals of Hematology, 2020, 99, 1643-1653.	1.8	3
85	Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation. Medicine (United States), 2020, 99, e23569.	1.0	6
86	Mutations Based on Next-Generation Sequencing May be Complementally to Prognostic Risk in Myelodysplastic Syndromes. Blood, 2020, 136, 42-43.	1.4	0
87	Development and Validation of a Prognostic Model for Transplant-Associated Thrombotic Microangiopathy Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 16-17.	1.4	0
88	Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia. Blood, 2020, 136, 4-5.	1.4	0
89	The significance of peri-transplantation minimal residual disease assessed by multiparameter flow cytometry on outcomes for adult AML patients receiving haploidentical allografts. Bone Marrow Transplantation, 2019, 54, 567-577.	2.4	19
90	Update of the "Beijing Protocol―haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 703-707.	2.4	28

#	Article	IF	CITATIONS
91	Minimal residual disease status determined by multiparametric flow cytometry pretransplantation predicts the outcome of patients with ALL receiving unmanipulated haploidentical allografts. American Journal of Hematology, 2019, 94, 512-521.	4.1	51
92	All- <i>trans</i> retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement–interleukin-1β loop. Haematologica, 2019, 104, 1661-1675.	3.5	25
93	Donor selection for haploidentical hematopoietic cell transplantation―practice guidance. Advances in Cell and Gene Therapy, 2019, 2, e42.	0.9	0
94	Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation. Clinical Immunology, 2019, 205, 49-56.	3.2	6
95	Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation. Annals of Hematology, 2019, 98, 1733-1742.	1.8	6
96	Incidence, Risk Factors, and Outcome of Immune-Mediated Neuropathies (IMNs) following Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1629-1636.	2.0	6
97	Early myeloid-derived suppressor cells (HLA-DRâ [~] /lowCD33+CD16â [~]) expanded by granulocyte colony-stimulating factor prevent acute graft-versus-host disease (GVHD) in humanized mouse and might contribute to lower GVHD in patients post allo-HSCT. Journal of Hematology and Oncology, 2019, 12, 31.	17.0	35
98	Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. Leukemia and Lymphoma, 2019, 60, 2181-2189.	1.3	15
99	Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia. Blood Advances, 2019, 3, 1416-1428.	5.2	18
100	Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation. Blood Advances, 2019, 3, 1303-1317.	5.2	43
101	Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation. Blood Advances, 2019, 3, 4312-4325.	5.2	27
102	Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Frontiers in Immunology, 2019, 10, 2516.	4.8	36
103	Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft?. Seminars in Hematology, 2019, 56, 201-208.	3.4	10
104	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. Clinical Cancer Research, 2019, 25, 1737-1748.	7.0	26
105	Hepatitis E virus infection after haploidentical haematopoietic stem cell transplantation: incidence and clinical course. British Journal of Haematology, 2019, 184, 788-796.	2.5	8
106	Effects of Low-Dose Glucocorticoid Prophylaxis on Chronic Graft-versus-Host Disease and Graft-versus-Host Disease–Free, Relapse-Free Survival after Haploidentical Transplantation: Long-Term Follow-Up of a Controlled, Randomized Open-Label Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 529-537.	2.0	11
107	Class I and II human leukocyte antibodies in pediatric haploidentical allograft candidates: prevalence and risk factors. Bone Marrow Transplantation, 2019, 54, 1287-1294.	2.4	7
108	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. Cancer Letters, 2019, 442, 193-201.	7.2	12

#	Article	IF	CITATIONS
109	Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation. Frontiers of Medicine, 2019, 13, 45-56.	3.4	26
110	Rituximab for Desensitization during HLA-Mismatched Stem Cell Transplantation in Patients with a Positive Donor Specific Anti-HLA Antibody: A Prospective Study. Blood, 2019, 134, 5622-5622.	1.4	0
111	Costimulatory Molecule DNAM-1 Is Essential for Optimal NK Education Post Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 3291-3291.	1.4	0
112	Genomic Landscape and Risk-Stratification for De Novo Acute Myeloid Leukemia with Normal Cytogenetics and No NPM1 or FLT3-itd Mutation. Blood, 2019, 134, 1421-1421.	1.4	0
113	Contribution of Myeloid-Drived Suppressor Cells to Leukemia Relapse in Patients with B-ALL Who Underwent Allo-HSCT. Blood, 2019, 134, 2010-2010.	1.4	Ο
114	Risk Factors and Different Therapeutic Patterns of Late-Onset Hemorrhagic Cystitis after Haploidentical Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 3261-3261.	1.4	0
115	Dead/H-Box Helicase 11 (DDX11) Mutations Correlate with Increased Relapse Risk in Persons with Acute Myeloid Leukaemia and Promote Proliferation and Survival of Human AML Cells in Vitro and in Immune Deficient Mice. Blood, 2019, 134, 2732-2732.	1.4	1
116	Interferon-a-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients with Low-Risk Acute Myeloid Leukemia. Blood, 2019, 134, 3823-3823.	1.4	1
117	Autophagy in Endothelial Cells Regulates Their Hematopoiesis Supporting Ability. Blood, 2019, 134, 4425-4425.	1.4	Ο
118	Observation on the Efficacy of Consolidation Chemotherapy Combined with Allogeneic Natural Killer Cell Infusion in the Treatment of Low and Moderate Risk AML. Blood, 2019, 134, 1378-1378.	1.4	0
119	Donor and Host Coexpressing KIR Ligands Promote NK Education Post Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2019, 134, 4519-4519.	1.4	0
120	The impact of donor characteristics on the invariant natural killer T cells of granulocyte-colony-stimulating factor-mobilized marrow grafts and peripheral blood grafts. Transplant Immunology, 2018, 48, 55-59.	1.2	3
121	Update on current research into haploidentical hematopoietic stem cell transplantation. Expert Review of Hematology, 2018, 11, 273-284.	2.2	20
122	Effect of the inÂvivo application of granulocyte colonyâ€stimulating factor on <scp>NK</scp> cells in bone marrow and peripheral blood. Journal of Cellular and Molecular Medicine, 2018, 22, 3025-3034.	3.6	15
123	Reversal of T Cell Exhaustion by the First Donor Lymphocyte Infusion Is Associated with the Persistently Effective Antileukemic Responses in Patients with Relapsed AML after Allo-HSCT. Biology of Blood and Marrow Transplantation, 2018, 24, 1350-1359.	2.0	39
124	Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia. Functional and Integrative Genomics, 2018, 18, 287-299.	3.5	15
125	Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1582-1587.	7.1	59
126	Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Annals of Hematology, 2018, 97, 967-975.	1.8	27

#	Article	IF	CITATIONS
127	Diminished expression of β2-GPI is associated with a reduced ability to mitigate complement activation in anti-GPIIb/IIIa-mediated immune thrombocytopenia. Annals of Hematology, 2018, 97, 641-654.	1.8	9
128	Inverse correlation of Vĺ2 ⁺ T ell recovery with <scp>EBV</scp> reactivation after haematopoietic stem cell transplantation. British Journal of Haematology, 2018, 180, 276-285.	2.5	23
129	Newly Generated CD4+ T Cells Acquire Metabolic Quiescence after Thymic Egress. Journal of Immunology, 2018, 200, 1064-1077.	0.8	23
130	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. Annals of Hematology, 2018, 97, 485-495.	1.8	14
131	Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients. Blood, 2018, 131, 1219-1233.	1.4	40
132	Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 600-608.	2.4	9
133	Haploidentical Transplantation Using Unmanipulated G-CSF-Primed Blood and Marrow as Allografts: Clinical Data and Challenges. , 2018, , 55-79.		0
134	The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2018, 97, 1547-1554.	1.8	15
135	MicroRNA-17-92 is required for T-cell and B-cell pathogenicity in chronic graft-versus-host disease in mice. Blood, 2018, 131, 1974-1986.	1.4	51
136	lgG synthesis rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be associated with the onset of CNS demyelination after haplo-HSCT. Annals of Hematology, 2018, 97, 1399-1406.	1.8	6
137	Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1936-1943.	2.0	25
138	Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease. Science China Life Sciences, 2018, 61, 902-911.	4.9	14
139	T cell exhaustion characterized by compromised MHC class I and II restricted cytotoxic activity associates with acute B lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation. Clinical Immunology, 2018, 190, 32-40.	3.2	24
140	Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. Science China Life Sciences, 2018, 61, 569-577.	4.9	8
141	Comparison of reference values for immune recovery between event-free patients receiving haploidentical allografts and those receiving human leukocyte antigen-matched sibling donor allografts. Frontiers of Medicine, 2018, 12, 153-163.	3.4	6
142	Thrombotic microangiopathy with concomitant <scp>GI</scp> aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome. European Journal of Haematology, 2018, 100, 171-181.	2.2	13
143	Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Chinese Medical Journal, 2018, 131, 2808-2816.	2.3	7
144	Relationship of Cell Compositions in Allografts with Outcomes after Haploidentical Transplantation for Acquired Severe Aplastic Anemia. Chinese Medical Journal, 2018, 131, 2185-2192.	2.3	5

#	Article	IF	CITATIONS
145	Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Frontiers in Immunology, 2018, 9, 3041.	4.8	50
146	The role of collateral related donors in haploidentical hematopoietic stem cell transplantation. Science Bulletin, 2018, 63, 1376-1382.	9.0	27
147	Evaluation of HistoCheck as a Predictor of Clinical Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1866-1872.	2.0	1
148	Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. Human Immunology, 2018, 79, 672-677.	2.4	11
149	Predicted indirectly recognizable HLA epitopes are not associated with clinical outcomes after haploidentical hematopoietic stem cell transplantation. Human Immunology, 2018, 79, 117-121.	2.4	7
150	Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation:Incidence and Clinical Course. Blood, 2018, 132, 5734-5734.	1.4	0
151	Poor NKG2C+ Adaptive NK Cell Recovery at Early Stage after Allo-HSCT Increased the Occurrence of Refractory Cytomegalovirus Infection. Blood, 2018, 132, 360-360.	1.4	0
152	Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. Annals of Hematology, 2017, 96, 567-574.	1.8	19
153	The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. Journal of Hematology and Oncology, 2017, 10, 44.	17.0	51
154	Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation. OncoImmunology, 2017, 6, e1284721.	4.6	28
155	Viral encephalitis after haploâ€identical hematopoietic stem cell transplantation: Causative viral spectrum, characteristics, and risk factors. European Journal of Haematology, 2017, 98, 450-458.	2.2	22
156	Recipientâ€donor KIR ligand matching prevents CMV reactivation postâ€haploidentical T cellâ€replete transplantation. British Journal of Haematology, 2017, 177, 766-781.	2.5	21
157	Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Longâ€ŧerm outcomes of a prospective randomized trial. Cancer, 2017, 123, 2881-2892.	4.1	63
158	Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. Oncolmmunology, 2017, 6, e1356152.	4.6	28
159	Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. Stem Cells and Development, 2017, 26, 1648-1661.	2.1	36
160	Cytomegalovirus-Specific T-Cell Transfer for Refractory Cytomegalovirus Infection After Haploidentical Stem Cell Transplantation: The Quantitative and Qualitative Immune Recovery for Cytomegalovirus. Journal of Infectious Diseases, 2017, 216, 945-956.	4.0	82
161	Effects of pre―and postâ€ŧransplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigenâ€matched or mismatched related donor allografts. American Journal of Hematology, 2017, 92, E659-E661.	4.1	19
162	The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission. Leukemia and Lymphoma, 2017, 58, 1135-1143.	1.3	27

#	Article	IF	CITATIONS
163	Reelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin β1 signaling. Journal of Cancer, 2017, 8, 2212-2222.	2.5	8
164	Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. Journal of Immunology Research, 2017, 2017, 1-8.	2.2	21
165	Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. Journal of Hematology and Oncology, 2017, 10, 134.	17.0	132
166	Ceramide synthesis regulates T cell activity and GVHD development. JCI Insight, 2017, 2, .	5.0	49
167	Impact of pre-transplant pulmonary infection developed in horizontal laminar flow unit on the outcome of subsequent allogeneic hematopoietic stem cell transplantation. Journal of Thoracic Disease, 2016, 8, 2219-2225.	1.4	2
168	Rapid Recovery of CD3+CD8+ T Cells on Day 90 Predicts Superior Survival after Unmanipulated Haploidentical Blood and Marrow Transplantation. PLoS ONE, 2016, 11, e0156777.	2.5	17
169	Early lymphocyte recovery predicts superior outcomes after unmanipulated haploidentical blood and marrow transplant for acute myeloid leukemia. Clinical Transplantation, 2016, 30, 954-958.	1.6	4
170	Controlled, Randomized, Open-Label Trial of Risk-Stratified Corticosteroid Prevention of Acute Graft-Versus-Host Disease After Haploidentical Transplantation. Journal of Clinical Oncology, 2016, 34, 1855-1863.	1.6	100
171	Factors affecting the CD34+ cell yields from the second donations of healthy donors: The steady-state lymphocyte count is a good predictive factor. Transfusion and Apheresis Science, 2016, 55, 311-317.	1.0	2
172	Clinical characteristics and risk factors of Intracranial hemorrhage in patients following allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2016, 95, 1637-1643.	1.8	27
173	Improved clinical outcomes of rhG-CSF-mobilized blood and marrow haploidentical transplantation compared to propensity score-matched rhG-CSF-primed peripheral blood stem cell haploidentical transplantation: a multicenter study. Science China Life Sciences, 2016, 59, 1139-1148.	4.9	13
174	Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. Oncolmmunology, 2016, 5, e1250992.	4.6	21
175	Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. Journal of Infection, 2016, 73, 261-270.	3.3	19
176	Lower incidence of acute GVHD is associated with the rapid recovery of CD4+CD25+CD45RA+ regulatory T cells in patients who received haploidentical allografts from NIMA-mismatched donors: A retrospective (development) and prospective (validation) cohort-based study. Oncolmmunology, 2016. 5. e1242546.	4.6	11
177	Increased Type 1 Immune Response in the Bone Marrow Immune Microenvironment of Patients with Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1376-1382.	2.0	33
178	How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?. Journal of Hematology and Oncology, 2016, 9, 35.	17.0	78
179	Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience. Seminars in Hematology, 2016, 53, 82-89.	3.4	48
180	Combined model of the EBMT score modified model and the HCT-CI improves the stratification of high-risk patients undergoing unmanipulated haploidentical blood and marrow transplantation. Leukemia and Lymphoma, 2016, 57, 2133-2139.	1.3	8

#	Article	IF	CITATIONS
181	The Clinical Significance of Monitoring Expression Level of Sil-TAL1 Fusion Gene after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 5800-5800.	1.4	Ο
182	Characteristics of Early Recovery of Double Negative T-Cell Subpopulations after Haploidentical Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 4589-4589.	1.4	0
183	Desialylation of Megakaryocytes Diminishes Platelet Production By Disrupting Megakaryocyte Adhesion, Migration and Proplatelet Formation in Chronic Immune Thrombocytopenia. Blood, 2016, 128, 165-165.	1.4	Ο
184	Lower Incidence of Acute Gvhd Is Associated with the Rapid Recovery of CD4+CD25+CD45RA+ Regulatory T Cells in Patients Who Received Haploidentical Allografts from NIMA-Mismatched Donors: A Retrospective (development) and Prospective (validation) Cohort-Based Study. Blood, 2016, 128, 4573-4573.	1.4	0
185	Polymorphisms of CTLA-4 Are Associated with Treatment Outcome in Multiple Myeloma Patients Receiving Bortezomib-Based Regimens. Blood, 2016, 128, 3323-3323.	1.4	Ο
186	Crucial Role of Complement Activation and IL-1Î ² in Bone Marrow Niche of Immune Thrombocytopenia. Blood, 2016, 128, 166-166.	1.4	0
187	Higher frequency of regulatory T cells in granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts compared with G-CSF-primed peripheral blood grafts. Journal of Translational Medicine, 2015, 13, 145.	4.4	24
188	Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. Journal of Translational Medicine, 2015, 13, 391.	4.4	24
189	Recipient expression of ligands for donor inhibitory KIRs enhances NKâ€cell function to control leukemic relapse after haploidentical transplantation. European Journal of Immunology, 2015, 45, 2396-2408.	2.9	42
190	The impact of donor characteristics on the immune cell composition of mixture allografts of granulocyte–colonyâ€stimulating factor–mobilized marrow harvests and peripheral blood harvests. Transfusion, 2015, 55, 2874-2881.	1.6	18
191	The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation. Annals of Hematology, 2015, 94, 1699-1705.	1.8	77
192	ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells. Haematologica, 2015, 100, 585-594.	3.5	38
193	IL-35 inhibits acute graft-versus-host disease in a mouse model. International Immunopharmacology, 2015, 29, 383-392.	3.8	11
194	Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets. Journal of Hematology and Oncology, 2015, 8, 84.	17.0	160
195	Monocytic and promyelocytic myeloidâ€derived suppressor cells may contribute to <scp>G</scp> â€ <scp>CSF</scp> â€induced immune tolerance in haploâ€identical allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2015, 90, E9-E16.	4.1	66
196	Improving Cytomegalovirus-Specific T Cell Reconstitution after Haploidentical Stem Cell Transplantation. Journal of Immunology Research, 2014, 2014, 1-12.	2.2	22
197	Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 440-449.	2.0	88
198	Association between an Impaired Bone Marrow Vascular Microenvironment and Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1190-1197.	2.0	49

#	Article	IF	CITATIONS
199	Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 929-936.	2.0	28
200	Haploidentical stem cell transplantation for the treatment of leukemia: current status. Expert Review of Hematology, 2014, 7, 635-647.	2.2	24
201	Non-traditional CD4+CD25â^'CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation. Journal of Translational Medicine, 2014, 12, 187.	4.4	12
202	Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood, 2014, 124, 843-850.	1.4	285
203	Risk-Stratification Directed Prophylaxis with Additional Low-Dose of Methylprednisolone Can Reduce Acute Graft-Versus-Host Disease for Patients with Hematological Malignancies after Allogeneic SCT: A Randomized, Controlled, Clinical Trial. Blood, 2014, 124, 40-40.	1.4	0
204	Negative association of donor age with CD34⺠cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests. Chinese Medical Journal, 2014, 127, 3597-601.	2.3	6
205	Association of an Impaired Bone Marrow Microenvironment with Secondary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 1465-1473.	2.0	114
206	Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?. Blood Reviews, 2013, 27, 55-62.	5.7	89
207	Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome. Leukemia and Lymphoma, 2013, 54, 2671-2677.	1.3	14
208	Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation. PLoS ONE, 2013, 8, e58735.	2.5	11
209	Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Current Opinion in Hematology, 2012, 19, 454-461.	2.5	40
210	Haploidentical Bone Marrow Transplantation Without T-Cell Depletion. Seminars in Oncology, 2012, 39, 653-663.	2.2	35
211	The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood, 2012, 119, 5584-5590.	1.4	107
212	Immune Reconstitution Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation Compared with HLA-Identical Sibling Transplantation. Journal of Clinical Immunology, 2012, 32, 268-280.	3.8	81
213	Characteristics and influencing factors of CD19+ B cell reconstitution in patients following haploidentical/mismatched hematopoietic stem cell transplantation. International Journal of Hematology, 2012, 96, 109-121.	1.6	11
214	Peripheral blood stem cell transplantation or bone marrow transplant in allogeneic settings: Which should be chosen?. Leukemia Research, 2012, 36, e116-e117.	0.8	2
215	Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Annals of Hematology, 2012, 91, 427-437.	1.8	40
216	Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 197-204.	2.0	58

#	Article	IF	CITATIONS
217	Conflicting Impact of Alloreactive NK Cells on Transplantation Outcomes after Haploidentical Transplantation: Do the Reconstitution Kinetics of Natural Killer Cells Create These Differences?. Biology of Blood and Marrow Transplantation, 2011, 17, 1436-1442.	2.0	29
218	Characterization of CD3+CD4â^'CD8â^' (double negative) T cells reconstitution in patients following hematopoietic stem-cell transplantation. Transplant Immunology, 2011, 25, 180-186.	1.2	18
219	Use of G-CSF-stimulated marrow in allogeneic hematopoietic stem cell transplantation settings: a comprehensive review. Clinical Transplantation, 2011, 25, 13-23.	1.6	36
220	The impact of graft composition on clinical outcomes in pediatric patients undergoing unmanipulated HLAâ€mismatched/haploidentical hematopoietic stem cell transplantation. Pediatric Blood and Cancer, 2011, 57, 135-141.	1.5	19
221	Clinical impact of absolute lymphocyte count on day 30 after unmanipulated haploidentical blood and marrow transplantation for pediatric patients with hematological malignancies. American Journal of Hematology, 2011, 86, 227-230.	4.1	18
222	Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,. Blood, 2011, 118, 4161-4161.	1.4	0
223	Comparable Immune Reconstitution Achieved Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation and HLA-Identical Sibling Transplantation. Blood, 2010, 116, 2312-2312.	1.4	0
224	Expression of CD62L on Donor CD4+ T Cells in Allografts: Correlation with Graft-Versus-Host Disease after Unmanipulated Allogeneic Blood and Marrow Transplantation. Journal of Clinical Immunology, 2009, 29, 696-704.	3.8	20
225	High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia. Annals of Hematology, 2009, 88, 1015-1024.	1.8	19
226	The impact of CD34 ⁺ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation. Pediatric Blood and Cancer, 2009, 53, 1100-1106.	1.5	21
227	Treating donor mice with rhIL-11 and rhG-CSF promotes transplant-tolerance and preserves the effects of GVL after allogeneic bone marrow transplantation. Leukemia Research, 2009, 33, 123-128.	0.8	3
228	Platelet Engraftment in Patients with Hematologic Malignancies following Unmanipulated Haploidentical Blood and Marrow Transplantation: Effects of CD34+ Cell Dose and Disease Status. Biology of Blood and Marrow Transplantation, 2009, 15, 632-638.	2.0	63
229	Expression profiles of adhesion molecules on naà ve T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulating factor. Transplant Immunology, 2009, 21, 228-233.	1.2	24
230	Influence of Lymphocyte Recovery on Outcome of Haploidentical Transplantation for Hematologic Malignancies. Medicine (United States), 2009, 88, 322-330.	1.0	23
231	Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2008, 14, 323-334.	2.0	72
232	Comparison of Transplant Donor- and Third-Party Donor-Derived CMV-Specific T Cells for CMV Infection After Allogenic Stem Cell Transplantation. SSRN Electronic Journal, 0, , .	0.4	0
233	Superiority of Leukemic Stem Cell-Based Minimal Residual Disease Assay to Traditional Multiparameter Flow Cytometry-Based Method for Relapse Prediction in AML Patients: A Prospective Study with Randomized Training and Validation Sets. SSRN Electronic Journal, 0, , .	0.4	0
234	Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment. Frontiers in Immunology, 0, 13, .	4.8	3

#	Article	IF	CITATIONS
235	Immune Reconstitution of Patients Who Recovered From Steroid-Refractory Acute Graft-Versus-Host Disease After Basiliximab Treatment. Frontiers in Oncology, 0, 12, .	2.8	2